Ritalin/Ritalin LA

Ritalin/Ritalin LA

methylphenidate

Manufacturer:

Novartis

Distributor:

DKSH
Concise Prescribing Info
Contents
Methylphenidate HCl
Indications/Uses
Dosage/Direction for Use
Ritalin Adult Narcolepsy 20-30 mg daily in 2-3 divided doses. Max: 60 mg daily. Childn & adolescent ≥6 yr ADHD Initially 5 mg once or bd w/ 5 or 10 mg gradual wkly increments. Max: 60 mg daily. Ritalin LA Adult Initially 20 mg once daily. Max: 80 mg daily.
Administration
May be taken with or without food: Take consistently either always w/ or always w/o food. Ritalin LA: May be swallowed whole. Alternatively, carefully open cap & sprinkle contents over room temp soft food (eg, applesauce). Swallow mixt immediately w/o chewing. Do not store for future use.
Contraindications
Hypersensitivity. Anxiety, tension; agitation; hyperthyroidism; preexisting CV disorders including severe HTN, angina, arterial occlusive disease, heart failure, congenital heart disease, cardiomyopathies, MI, arrhythmias & channelopathies; glaucoma; phaeochromocytoma. Diagnosis or family history of Tourette's syndrome. Concomitant use w/ MAOIs or w/in min of 2 wk discontinuation.
Special Precautions
Discontinue use if seizure frequency increases. Not indicated in all cases of ADHD. Not to be used in patients w/ known structural cardiac abnormalities or other serious cardiac disorders; preexisting CNS abnormalities eg, cerebral aneurysm &/or other vascular abnormalities eg, vasculitis or preexisting stroke. Not to be initiated in patients w/ acute psychosis, mania or suicidality. Emergent/exacerbation of psychiatric symptoms; psychotic symptoms including visual & tactile hallucinations or mania; emergent aggressive behavior, suicidal tendency. Conditions compromised by increased BP or heart rate eg, preexisting HTN; priapism; emotionally unstable patients eg, history of drug dependence or alcoholism. Marked tolerance & psychological dependence. Assess patients for preexisting CV disorders & family history of sudden death & ventricular arrhythmia prior to initiation; neurological/psychiatric signs & symptoms after initiation; preexisting psychiatric disorders & family history of psychiatric disorders; measure wt & height prior to treatment; family history & clinical evaluation for Tourette's syndrome. Evaluate need for treatment regimen adjustment w/ emergent/exacerbation of baseline aggressive behavior. Monitor for clinical worsening, suicidal behavior/thoughts, unusual changes in behavior; emergence/worsening of tics & growth development. Perform complete & differential blood & platelet counts in long-term therapy. Avoid abrupt w/drawal. Misuse may be associated w/ sudden death & other serious CV adverse events. Not recommended in concomitant use w/ serotonergic drugs eg, SSRIs & SNRIs. May affect ability to drive & use machines. Not to be given during pregnancy. Lactation. Not to be used in childn <6 yr.
Adverse Reactions
Nasopharyngitis; decreased appetite; nervousness, insomnia; nausea, dry mouth. Anxiety, restlessness, sleep disorder, agitation, depression, aggression, bruxism; dyskinesia, tremor, headache, drowsiness, dizziness; tachycardia, palpitation, arrhythmias, BP & heart rate changes; cough; abdominal pain, vomiting, dyspepsia, toothache; rash, pruritus, urticaria, fever, scalp hair loss, hyperhidrosis; arthralgia; feeling jittery; decreased wt; Raynaud's phenomenon, peripheral coldness.
Drug Interactions
Decreased effectiveness of antihypertensives. Possible hypertensive crisis w/ MAOIs. Exacerbated CNS effects w/ alcohol. Risk of sudden increased BP & heart rate w/ anesth. Serious adverse events eg, sudden death w/ centrally acting α2-agonists eg, clonidine. Development of serotonin syndrome w/ serotonergic drugs. Pharmacodynamic interactions w/ direct & indirect dopamine agonists eg, DOPA, TCAs, antipsychotics. Counteracted mechanism of action w/ antipsychotics. Induced false +ve laboratory tests for amphetamines. Potential interaction w/ coumarin anticoagulants, anticonvulsants (eg, phenobarb, phenytoin, primidone), phenylbutazone; BP-elevating drugs.
MIMS Class
Other CNS Drugs & Agents for ADHD
ATC Classification
N06BA04 - methylphenidate ; Belongs to the class of centrally-acting sympathomimetics. Used as CNS stimulant.
Presentation/Packing
Form
Ritalin IR tab 10 mg
Packing/Price
100's;200's;30's
Form
Ritalin LA MR cap 20 mg
Packing/Price
30's
Form
Ritalin LA MR cap 30 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in